Does radical cystectomy outperform other bladder preservative treatments in elderly patients with advanced bladder cancer?

Chen, Chin-Li; Liu, Chin-Yu; Cha, Tai‐Lung; Hsu, Chien‐Yeh; Chou, Yu-Ching; Wu, Sheng‐Tang; Meng, En; Sun, Guang‐Huan; Yü, Dah‐Shyong; Tsao, Chih-Wei

doi:10.1016/j.jcma.2015.05.003

Cited by 10 publications

(8 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Laparoscopic and robotic approaches are performed at the selected institutions. Bladder preservative treatment with chemoradiotherapy in patients with advanced bladder cancer is also one of treatment options with the short-and long-term overall survivals similar to that of radical cystectomy in patients older than 76 years (26).…”

Section: Bladder Cancermentioning

confidence: 99%

Urologic cancer in Taiwan

Hung

Yang

2016

Jpn. J. Clin. Oncol.

View full text Add to dashboard Cite

For the past three decades, cancer is the number one cause of death in Taiwan. An increasing trend in the incidence of urologic cancers has also been noticed since 1979. In 2012, urologic cancer accounted for 10.0% of all the new malignant cases. Prostate, bladder and kidney cancers are the most common types. Metastatic prostate cancer still accounted for nearly 30% of new cases in Taiwan between 2004 and 2012. There are several specifically noticeable characteristics of urothelial carcinoma in Taiwan, associated with arseniasis and aristolochic acid. The diagnosis and treatment of urologic cancer mainly follows the current international guidelines. The development of minimal invasive surgery, especially DaVinci robotic surgical system, has made a marked change in the surgical treatment of urologic cancer. Meanwhile, newer systemic agents also commence and improve our standard of care. However, treatment decisions are greatly influenced by the National Health Insurance coverage. The current national cancer registry system should be renovated more comprehensively in order to gain better insight into specific features of urologic cancer in Taiwan.

show abstract

Section: Bladder Cancermentioning

confidence: 99%

Urologic cancer in Taiwan

Hung

Yang

2016

Jpn. J. Clin. Oncol.

View full text Add to dashboard Cite

show abstract

“…Currently, no specific treatment guidelines exist for patients with pancreatic-kidney transplant patients that develop bladder cancer [ 1 , 3 ]. The two most common treatment options for bladder cancer in the general population are RC or bladder TMT [ 10 , 11 ]. For MIBC, the preferred treatment is RC with urinary diversion [ 11 , 12 ].…”

Section: Discussionmentioning

confidence: 99%

“…TMT consists of complete TURBT followed by chemotherapy and radiation [ 4 , 10 ] which evaluated the outcomes and the overall survival rates in 160 patients with bladder cancer treated with either RC, TURBT, TMT, or palliative care with chemotherapy and radiation. The study found no difference in treatment outcomes for advanced UCC with RC and TURBT for patients over 76 years old; however, those under the age of 76 with treated with RC had increased disease-specific survival without recurrence [ 10 ]. Notably, none of these patients had history of SOT which may have altered treatment without chemoradiotherapy restrictions [ 10 ].…”

Section: Discussionmentioning

confidence: 99%

Conservative Management of Muscle Invasive Bladder Cancer in Kidney-Pancreas Transplant Patient

Glosser

Lombardi

Ekwenna

2022

Case Reports in Transplantation

View full text Add to dashboard Cite

Introduction. Solid organ transplant increases the risk for muscle-invasive bladder cancer (MIBC). Although a common tumor, urothelial cell carcinoma (UCC) of the bladder in patients with kidney-pancreas transplants is scarcely reported. Case Presentation. A 65-year-old male with history of type 1 diabetes and a 14-year status post deceased donor pancreas-kidney transplant presented with 3 weeks of gross hematuria. CT scan showed multiple bladder masses. Transurethral resection of bladder tumor (TURBT) showed papillary UCC. 5 months later, the patient reported new-onset gross hematuria. TURBT showed MIBC. The patient elected for bladder-preserving TMT. On cystoscopy there was no gross evidence of carcinoma at 3.5 years of follow up. Discussion. Currently, no specific management guidelines target this population with MIBC. The first-line treatment for MIBC is radical cystectomy (RC) with neoadjuvant chemotherapy. For patients that are medically unfit or unwilling to undergo RC, trimodal therapy (TMT) is an alternative. TMT for bladder cancer consists of complete tumor resection with chemotherapy and radiation. This report demonstrates a unique case of a patient with kidney-pancreas transplant diagnosed with MIBC treated with TMT that has no evidence of gross tumorigenesis at 3.5 years after diagnosis. Our findings suggest that trimodal therapy should be considered for treatment of MIBC in patients with kidney-pancreatic transplants to preserve the donated allografts.

show abstract

“…Hence, the recurrence rate is not low, with an overall 5year survival rate of 15-20% (4,5). Additionally, surgical treatment and chemotherapy are quite limited for advanced bladder cancer (6,7). This high recurrence rate may be partly explained by the poorly understood pathogenesis of BCa (8).…”

Section: Introductionmentioning

confidence: 99%

Construction of a Co-Expression Network for lncRNAs and mRNAs Related to Urothelial Carcinoma of the Bladder Progression

2022

View full text Add to dashboard Cite

Carcinoma of urinary bladder is the most familiar cancer of the urinary tract, with the highest incidence in men. However, its prognosis and treatment have not improved significantly in the last 30 years. The main reason for this may be related to the alteration and regulation of genes. These alterations in genes that play a crucial role in cell cycle regulation may result in high-grade tumors and may alter drug sensitivity. Notably, the role of lncRNA in bladder cancer, especially the lncRNA-mRNA regulatory network, has not been fully elucidated. In this manuscript, we compared RNA sequencing (RNA-seq) data from 19 normal bladder tissues and 411 primary bladder tumor tissues using The Cancer Genome Atlas (TCGA) data bank, subjected differentially expressed mRNAs and lncRNAs to weighted gene co-expression network analysis, and screened out modules highly correlated with tumor progression. Subsequently, a lncRNA-mRNA co-expression network was built, and two key mRNAs were identified via COX regression analysis. Kaplan-Meier curve analysis revealed that the overall survival of sick people in the high-risk section was significantly shorter than those in the low-risk section. Therefore, this lncRNA-mRNA-based co-expression pattern may be used clinically to predict the prognosis of carcinoma of urinary bladder people. Our study not only provides a genetic target for carcinoma of urinary bladder therapy but also provides new ideas for people in the medical profession to discover the treatment of various tumors.

show abstract

Does radical cystectomy outperform other bladder preservative treatments in elderly patients with advanced bladder cancer?

Abstract: The short- and long-term OS rates of the three modalities were similar in those older than 76 years. Therefore, patients younger than age 76 years are likely to have a better outcome undergoing radical cystectomy for advanced UCB.

Cited by 10 publications

References 22 publications

Urologic cancer in Taiwan

Urologic cancer in Taiwan

Conservative Management of Muscle Invasive Bladder Cancer in Kidney-Pancreas Transplant Patient

Construction of a Co-Expression Network for lncRNAs and mRNAs Related to Urothelial Carcinoma of the Bladder Progression

Contact Info

Product

Resources

About